ATE525355T1 - 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1 - Google Patents

1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1

Info

Publication number
ATE525355T1
ATE525355T1 AT07748146T AT07748146T ATE525355T1 AT E525355 T1 ATE525355 T1 AT E525355T1 AT 07748146 T AT07748146 T AT 07748146T AT 07748146 T AT07748146 T AT 07748146T AT E525355 T1 ATE525355 T1 AT E525355T1
Authority
AT
Austria
Prior art keywords
äbenzoyl
butyluacetidine
aminoü
phenyl
derivatives
Prior art date
Application number
AT07748146T
Other languages
English (en)
Inventor
Anders Johansson
Johan Johansson
Carl-Gustav Sigfridsson
Original Assignee
Albireo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE525355(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Albireo Ab filed Critical Albireo Ab
Application granted granted Critical
Publication of ATE525355T1 publication Critical patent/ATE525355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT07748146T 2006-05-18 2007-05-16 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1 ATE525355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80157706P 2006-05-18 2006-05-18
PCT/SE2007/000482 WO2007136324A1 (en) 2006-05-18 2007-05-16 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1

Publications (1)

Publication Number Publication Date
ATE525355T1 true ATE525355T1 (de) 2011-10-15

Family

ID=38723558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07748146T ATE525355T1 (de) 2006-05-18 2007-05-16 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1

Country Status (23)

Country Link
US (1) US8106208B2 (de)
EP (1) EP2024354B1 (de)
JP (1) JP5196381B2 (de)
KR (1) KR101429779B1 (de)
CN (1) CN101472910B (de)
AR (1) AR060956A1 (de)
AT (1) ATE525355T1 (de)
AU (1) AU2007253666B2 (de)
BR (1) BRPI0712405A2 (de)
CA (1) CA2652443C (de)
DK (1) DK2024354T3 (de)
ES (1) ES2373335T3 (de)
IL (1) IL195197A (de)
MX (1) MX2008014686A (de)
MY (1) MY147474A (de)
NO (1) NO20084674L (de)
PL (1) PL2024354T3 (de)
PT (1) PT2024354E (de)
RU (1) RU2439067C2 (de)
TW (1) TW200813006A (de)
UY (1) UY30356A1 (de)
WO (1) WO2007136324A1 (de)
ZA (1) ZA200809909B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
CA2663280A1 (en) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
AU2008221673B2 (en) * 2007-03-08 2013-03-28 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
CA2721303C (en) 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
JP2013540159A (ja) * 2010-10-22 2013-10-31 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ阻害剤としてのピペリジン−４−イル−アゼチジンジアミド
US8835417B2 (en) * 2011-09-30 2014-09-16 Janssen Pharmaceutica Nv Crystalline hydrochloride salt of (1-(4-fluorophenyl)-1H-indol-5-yl)-(3-(4-(thiazole-2-carbonyl)piperazin-1-yl)azetidin-1-yl)methanone
CN104529833B (zh) * 2014-12-10 2016-04-20 广东东阳光药业有限公司 取代的环丁烷羧酸类化合物及其用途
KR102476938B1 (ko) 2017-12-07 2022-12-13 기초과학연구원 핫전자 기반의 산화물-금속 하이브리드 역촉매

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310066D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
GB9325074D0 (en) 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9502644D0 (en) 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9601202D0 (en) 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9601697D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
GB9812037D0 (en) 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
CA2336806A1 (en) * 1998-07-10 2000-01-20 Keith Russell N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922519D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
SE0004827D0 (sv) 2000-12-22 2000-12-22 Astrazeneca Ab Therapeutic compounds
SE0103795D0 (sv) 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of överactive bladder
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
CN101203511A (zh) * 2005-06-23 2008-06-18 阿斯利康(瑞典)有限公司 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
CN101208327A (zh) * 2005-06-23 2008-06-25 阿斯利康(瑞典)有限公司 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
AR056087A1 (es) * 2005-09-29 2007-09-19 Astrazeneca Ab Derivados de azetidina como antagonistas de receptores de neuroquina nk
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica

Also Published As

Publication number Publication date
UY30356A1 (es) 2008-01-02
JP5196381B2 (ja) 2013-05-15
JP2009537516A (ja) 2009-10-29
ES2373335T3 (es) 2012-02-02
HK1121758A1 (en) 2009-04-30
AU2007253666A1 (en) 2007-11-29
EP2024354B1 (de) 2011-09-21
CA2652443A1 (en) 2007-11-29
CN101472910B (zh) 2014-03-26
EP2024354A1 (de) 2009-02-18
IL195197A (en) 2013-10-31
CA2652443C (en) 2014-01-14
MY147474A (en) 2012-12-14
AR060956A1 (es) 2008-07-23
PT2024354E (pt) 2011-12-19
KR101429779B1 (ko) 2014-08-19
KR20090018926A (ko) 2009-02-24
AU2007253666B2 (en) 2012-03-15
RU2008149927A (ru) 2010-06-27
BRPI0712405A2 (pt) 2012-10-16
US8106208B2 (en) 2012-01-31
WO2007136324A1 (en) 2007-11-29
EP2024354A4 (de) 2009-11-11
US20070270398A1 (en) 2007-11-22
RU2439067C2 (ru) 2012-01-10
ZA200809909B (en) 2009-08-26
MX2008014686A (es) 2009-02-10
CN101472910A (zh) 2009-07-01
NO20084674L (no) 2009-01-29
TW200813006A (en) 2008-03-16
DK2024354T3 (da) 2012-01-16
IL195197A0 (en) 2009-08-03
PL2024354T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP1981526A4 (de) Adiponectin zur behandlung verschiedener erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE484279T1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties